Bisphosphonates in kidney disease:​ safety first

wbldb

Khairallah, Pascale¹; Nickolas, Thomas L.²

Bisphosphonates in kidney disease: safety first

J Bone Miner Res. May 2021;36(5):817-819

Cited Works (5)

Year	Entry
2009	KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int. August 2009;76(suppl 113):S1-S130.
2018	Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD. Fracture prevention with zoledronate in older women with osteopenia. NEJM. December 20, 2018;379(25):2407-2416.
2006	Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. November 2006;17(11):3223-3232.
2005	Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. March 2005;90(3):1294-1301.
2020	Fujita R, Ota M, Sato D, Nakazawa D, Kimura-Suda H, Nakamura F, Shimizu T, Kobayashi H, Iwasaki N, Takahata M. Comparison of the efficacy and renal safety of bisphosphonate between low-dose/high-frequency and high-dose/low-frequency regimens in a late-stage chronic kidney disease rat model. Calcif Tiss Int. October 2020;107(4):389-402.